Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy
This trial is active, not recruiting.
|Sponsor||University of Arkansas|
|Start date||January 2010|
|End date||December 2019|
|Trial size||200 participants|
|Trial identifier||NCT01539486, 112684|
The intent for this study is to do a retrospective chart review of all patients who have undergone minimally invasive parathyroidectomy for primary hyperthyroidism. All data collected will be recorded under assigned identification numbers that will have no association with medical record or hospital numbers. Identifying characteristics will include age and sex. Anonymity will be upheld. The patient/family will not be contacted directly. All information will be obtained from the medical chart. Demographics, location, preoperative PTH levels and intraoperative Ex-Vivo gamma counts, co-morbid conditions, and the outcome based on the hospital notes will be obtained from patients' charts and will be transferred to a secure database. It is our hypothesis that there is a linear relationship between immediate preoperative parathyroid hormone (PTH) levels and Ex-Vivo gamma counts and the aim of this study is to better describe this relationship.
Retrospective Chart Review
time frame: Retrospective Chart Review
Male or female participants from 18 years up to 90 years old.
Inclusion Criteria: - Patients must be between the ages of 18 and 90 years old who have documented primary hyperparathyroidism and have undergone minimally invasive parathyroidectomy. Exclusion Criteria: - Patients who have not had both intraoperative parathyroid hormone (PTH) levels and Gamma counts during their parathyroidectomy - Patients who have parathyroidectomies for reasons other than primary hyperparathyroidism.
|Official title||Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy|
|Principal investigator||Brendan Stack, MD|
Call for more information